Taiwan entered an aging society in 2018 and is projected to become a super-aged society by 2025. With the increasing elderly population, age-related diseases have become an urgent issue in modern society. According to 2018 statistics from the Ministry of Health and Welfare, the prevalence of sarcopenia among individuals aged 65 and above in Taiwan is 23.6% in men and 18.6% in women. Sarcopenia is a major contributor to disability in older adults. It is characterized by age-related loss of skeletal muscle mass, decreased muscle strength, and reduced physical performance, which may lead to disability, reduced quality of life, loss of independence, and increased risk of mortality. Previous studies have shown that appropriate nutrition and exercise can delay the onset of sarcopenia and even increase muscle mass, potentially reversing the condition. This study is an extension of the project titled "Assessment of the Intervention Effectiveness of Branched-chain Amino Acids(BCAA) Combined With Medium-chain Fatty Acid(MCFA) Products in Sarcopenia Among Middle-aged and Elderly Individuals". It is an interventional clinical study that recruits middle-aged and older patients with sarcopenia or pre-sarcopenia, using resistance training as the intervention. The results will be compared with the two original groups from the previous study to evaluate whether there are differences in intervention outcomes between resistance training and nutritional supplementation.
Age range
50 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
the scale of sarcopenia
Timeframe: Baseline, 8 weeks
the scale of sarcopenia
Timeframe: Baseline, 8 weeks
the scale of sarcopenia
Timeframe: Baseline, 8 weeks